Cellectar Biosciences to Present at the 9th Annual Biotech Showcase

| January 5, 2017

article image
Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announces today that President and CEO, Jim Caruso will present at the Biotech Showcase in San Francisco on January 11, 2017 at 10:00 AM PT in Room 2 (Ballroom Level). “We look forward to discussing the continued advancement of our lead PDC program, CLR 131, as well as providing relevant updates on our other product candidates and corporate performance,” said Mr. Caruso.

Spotlight

Icumulus

iCumulus is a new-age global fulfilment platform, leading the revolution of e-commerce, turning it into a totally shared & unified global economy. iCumulus connects your business to a network of global logistics providers, creating a unique shared ecosystem with the most competitive shipping rates. Unlike traditional logistics providers, iCumulus scales not by assets, staff or inventory, but by connecting true demand to supply ensuring best consumer experience. Our comprehensive cloud based e-fulfilment platform manages all distributions, purchasing, into store and consumer deliveries at no additional cost. We want our customers to be free to deal with what's important to them - service their customers, allowing them grow sales and reach new markets.

OTHER ARTICLES

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | April 17, 2020

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More

Top 10 biotech IPOs in 2019

Article | April 17, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | April 17, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Spotlight

Icumulus

iCumulus is a new-age global fulfilment platform, leading the revolution of e-commerce, turning it into a totally shared & unified global economy. iCumulus connects your business to a network of global logistics providers, creating a unique shared ecosystem with the most competitive shipping rates. Unlike traditional logistics providers, iCumulus scales not by assets, staff or inventory, but by connecting true demand to supply ensuring best consumer experience. Our comprehensive cloud based e-fulfilment platform manages all distributions, purchasing, into store and consumer deliveries at no additional cost. We want our customers to be free to deal with what's important to them - service their customers, allowing them grow sales and reach new markets.

Events